FDA inspection
Wuhan Hongren Biopharmaceutical Inc.: FDA inspection ending Sep 4, 2024
FDA inspection 1251337 · Voluntary Action Indicated (VAI) · Wuhan
Key facts
| Inspection ID | 1251337 |
|---|---|
| Firm | Wuhan Hongren Biopharmaceutical Inc. |
| FEI number | 3025298361 |
| Address | Building B4, Biolake, No. 666, Gaoxin Road, Wuhan East Lake High-Tech Development Zone |
| City | Wuhan |
| Fiscal year | 2024 |
| Inspection end date | Sep 4, 2024 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Generic Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data